TD Cowen Maintains Buy on Humacyte, Raises Price Target to $1.5

Benzinga Newsdesk www.benzinga.com Positive 78.0%

Neg 0% Neu 0% Pos 78%

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price target from $1 to $1.5.